Developer docs
API playgroundTry for free, no card

Search company profiles

QMENTA

Full company profile

uuid0000ezu

Namestring
QMENTA
Legal namestring
Mint Labs, Inc.
Websiteurl
qmenta.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

QMENTA (legal entity Mint Labs, Inc.) is a Boston-headquartered software company, founded in 2013, that operates a cloud-native AI imaging platform purpose-built for regulated clinical trials and neuroimaging research. The platform unifies imaging data ingestion (DICOM, NIfTI, BIDS formats), automated quality control, AI biomarker analysis, and regulatory-grade audit trails into a single governed data layer, with FDA 510(k) clearance and compliance with HIPAA, GDPR, and FDA Title 21 CFR Part 11. Core technical architecture is Docker-container-based and runs on hybrid cloud infrastructure (including Google Cloud Platform), exposing a Python SDK and Jupyter-compatible environment that enables third-party algorithm developers to package and distribute imaging AI tools via a revenue-sharing marketplace.

The company serves four primary customer segments: pharmaceutical sponsors and CROs running imaging endpoints in regulated trials (the primary segment), academic research institutions and imaging core labs, AI algorithm developers seeking a validated clinical deployment channel, and hospitals/healthcare providers. A secondary Legal vertical sells automated DTI quantification (Q-FiberMapper) to law firms and imaging centers on a pay-per-scan basis for TBI litigation. Revenue is generated through enterprise SaaS subscriptions (custom-priced, annual contracts for trials and core labs), usage-based analysis credits (freemium entry with 5 credits), SDK marketplace commissions, and tiered Neuro Data Services subscriptions (Tier 1-4 curated datasets). Named customers include Bayer, Amylyx, Cleveland Clinic, UCSF, NIH, Massachusetts General Hospital, and Alzamend Neuro, with the platform deployed across 250+ imaging sites and processing 16 million images covering 1.3 million subjects.

QMENTA goes to market through a hybrid motion combining direct enterprise field sales (targeting sponsors, CROs, and core labs) with product-led self-serve onboarding (free trial, 5 credits), event-driven demand generation at RSNA and CNS Summit, and developer relations via the SDK and GitHub community. Marketing channels emphasize thought leadership content, scientific case studies, and PR around regulatory milestones. Distribution covers North America (Boston HQ), Europe (Barcelona EU HQ), and an active expansion push into Asia-Pacific via a strategic advisor appointed in 2025. The company operates with 11-50 employees and has raised approximately $10M cumulatively across multiple small rounds since inception, with the most recent disclosed funding of $3.8M led by Flashpoint in July 2020.

Short descriptiontext

QMENTA is a Boston-based, FDA 510(k)-cleared cloud platform that provides AI-powered medical imaging analysis, automated quality control, and regulatory-grade data management for pharmaceutical sponsors, CROs, academic research institutions, and AI algorithm developers running clinical trials and neuroimaging research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging platform, clinical trial imaging, neuroimaging AI, imaging biomarkers, centralized image review
Industry3 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Clinical Trial Medical Imaging Software
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1SaaS Platform Subscription
TypeSubscription Recurring
Description

QMENTA operates as a cloud-based SaaS platform where customers pay subscription fees for access to the Imaging Hub, Central Review, and AI biomarker tools. Pricing is subscription-based, typically billed annually, with tiered plans based on usage volume, number of users, and analysis credits. Enterprise contracts cover sponsors, CROs, and core labs on a single platform.

qmenta.com
2Usage-Based Analysis Credits
TypeUsage Based
Description

Customers receive or purchase analysis credits to run AI imaging biomarker tools and workflows on the platform. Each analysis consumes one credit regardless of workflow complexity. Free trial users receive 5 credits. Enterprise contracts define credit allocations and parallel analysis capacity.

support.qmenta.com
3SDK / Tool Catalog Marketplace
TypeMarketplace Commission
Description

Third-party developers integrate algorithms into QMENTA's tool catalog via the SDK under revenue-sharing agreements. QMENTA markets, distributes, and sells the tools, retaining a share of the revenue. This creates a marketplace commission stream.

qmenta.com
4Neuro Data Services
TypeData Monetisation
Description

Curated and annotated neurology imaging datasets sold in tiered levels (Tier 1–4), ranging from aggregated de-identified data to integrated multi-modal datasets with expert radiology assessments and genomic/Real World Data. Over 10 million neurology images have been exchanged or stored on the platform.

qmenta.com
5Pay-per-Scan (Legal Product)
TypeTransaction Fee
Description

The QMENTA Legal product (Q-FiberMapper for TBI litigation) operates on a pay-per-scan model with no commitment required, targeting law firms and imaging centers directly.

qmenta.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details4 tiers
1Free Trial
ModelFreemiumBilling cadencePay-as-you-go
Notes

New users receive 5 free analysis credits upon account activation. One credit equals one complete analysis (even if consisting of multiple steps).

support.qmenta.com
2Subscription Plans (Custom Enterprise)
ModelSubscriptionBilling cadenceAnnual
Notes

Enterprise contracts for sponsors, CROs, and core labs include multi-user access, custom credit allocations, and parallel analysis capacity. Pricing is custom/quote-based. Annual billing is standard.

qmenta.com
3Legal - Pay-per-Scan
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Q-FiberMapper for TBI litigation is offered on a pay-per-scan basis with no commitment required, no specialist needed. Targeted at law firms and imaging centers.

qmenta.com
4Neuro Data Services (Tiers 1–4)
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Four tiers of curated neurology imaging data: Tier 1 (aggregated/tagged/de-identified), Tier 2 (+ disease-specific neuroimaging), Tier 3 (+ expert radiology assessments), Tier 4 (+ genomic/Real World Data integration). Custom pricing based on tier and data volume.

qmenta.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Neuro Data Services
Description

Curated real-world neurology imaging data services with tiered levels of augmented data for AI training, retrospective studies, and biomarker research.

qmenta.com
+1 more record
Core offering1 text field

QMENTA provides a cloud-native AI imaging platform for clinical trials and research that governs neuroimaging data from first scan through FDA submission. The platform combines an Imaging Hub (data ingestion, standardization, storage, AI biomarker analysis, and real-time quality control) with a Central Review capability for regulatory-grade endpoint review. QMENTA also operates an SDK-powered tool catalog marketplace for third-party AI algorithms and a curated Neuro Data Services offering across four data tiers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 81% cost reduction vs. on-premise imaging infrastructure ($600K vs. $3.2M) and $1.83M vs. cloud DIY for a 20-site clinical trial scenario
+6 more records
Product overview1 text field

QMENTA is a cloud-native medical imaging platform for clinical trials and research, built as a unified platform-plus-modules architecture. The core QMENTA Platform provides the central infrastructure with the Imaging Hub as the primary interface, which encompasses the Imaging Management System, Smart Uploader, Imaging Cloud storage, and AI Imaging Biomarkers. The platform is offered in three product tiers: Trials (governed neuroimaging for regulated studies), Foundation (AI development and deployment), and Legal (TBI litigation). Key modules include the Central Review Platform for regulatory-grade imaging endpoint review and the SDK for custom algorithm integration. Neuro Data Services provides curated data across four tiers. The platform processes over 16 million images across 250+ sites with FDA 510(k) clearance and zero nonconformities in external pharma audits.

Product and service5 records
1QMENTA Platform / Imaging Hub
CategoryCore platform
Description

An all-in-one cloud-native imaging platform for clinical trials that provides governed neuroimaging data management, AI analysis, and regulatory-grade evidence production across disease areas, imaging modalities, and trial phases. Sold to pharmaceutical sponsors, CROs, core labs, academic centers, hospitals, and AI firms as the core enterprise offering.

2Central Review Platform
CategoryRegulatory imaging review
Description

Regulatory-grade centralized image review system for imaging endpoints in long-duration oncology and CNS trials, providing longitudinal consistency monitoring, FDA Title 21 CFR Part 11-compliant electronic signatures, audit trails, and access controls. Sold to pharma sponsors, CROs, and core labs.

3Neuro Data Services
CategoryCurated imaging data services
Description

Curated real-world neurology imaging data service across four tiers: aggregated/tagged clinical data (Tier 1), disease-specific neuroimaging (Tier 2), expert radiology assessments (Tier 3), and integration with genomic/Real World Data (Tier 4). Sold to AI firms, pharma sponsors, and researchers.

4QMENTA Software Development Kit (SDK)
CategoryDeveloper toolkit / algorithm marketplace
Description

Python-based SDK and developer toolkit enabling algorithm developers to package, test, and distribute custom digital biomarker algorithms on the QMENTA platform via Docker containers, with monetization through a revenue-sharing tool catalog marketplace. Targeted at AI imaging biomarker developers.

5Q-FiberMapper (Legal Product)
CategoryLegal medical imaging
Description

Automated DTI quantification tool for TBI litigation that performs automated segmentation of 33 white matter fiber tracts. Sold on a pay-per-scan basis with no commitment required. Targeted at law firms and imaging centers handling TBI cases.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Dr. Montserrat Barceló
Strategic tierKey AdvisoryTypeOthersAnnounced on2026-03-11
Description

Dr. Montserrat Barceló was appointed as strategic advisor to QMENTA to support global growth and enterprise expansion, with particular focus on Europe and Asia-Pacific markets. Barceló brings healthcare and clinical research leadership experience from TFS HealthScience, Veristat, and other organizations.

einpresswire.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-03
Description

Alzamend Neuro partnered with QMENTA to advance AI-powered imaging for its Phase II clinical trial of AL001 at Massachusetts General Hospital (MGH). QMENTA provides AI-powered imaging analysis for head-to-head studies comparing AL001 versus lithium carbonate products for lithium blood levels and neuroimaging endpoints.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

QMENTA is partnered with EIT Health, a European initiative supported by the EU that fosters healthcare innovation. QMENTA's logo and partnership are displayed on its website, indicating collaborative alignment on healthcare innovation initiatives. EIT Health is listed as an official partner.

4Curated Neurology Imaging Data Partners
Strategic tierSupportingTypeOthers
Description

QMENTA's Neuro Data Services leverages a network of highly qualified partners to provide curated and annotated real-world neurology imaging and clinical data at four tiered levels. These partners provide data aggregation, disease-specific neuroimaging annotation, expert radiology assessments, and genomic/Real World Data integration.

qmenta.com
Strategic tierInfrastructureTypeTechnology or Integration
Description

QMENTA's privacy policy identifies Google Cloud Platform as a third-party data processor used both inside and outside the EEA. GCP provides cloud infrastructure and data storage services for the QMENTA platform.

Strategic tierInfrastructureTypeTechnology or Integration
Description

HubSpot is listed as a third-party data processor in QMENTA's privacy policy. Used for marketing automation, CRM, and website analytics. Data is processed both inside and outside the EEA.

Strategic tierInfrastructureTypeTechnology or Integration
Description

Atlassian is listed as a third-party data processor in QMENTA's privacy policy, used for internal collaboration and documentation management (e.g., Confluence, Jira).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clario is a clinical trial imaging and endpoint services company offering central reading, image management, and AI-enabled analytics for pharma and CROs. Directly comparable to QMENTA's Trials and Central Review products for the same sponsor and CRO buyer set.

TypeDirect peer
Description

Medidata's Rave Imaging provides central imaging management, reviewer workflows, and AI biomarker integration within a leading EDC platform. Highly comparable to QMENTA's governed imaging data layer for regulated trials, with a much larger installed base in pharma R&D.

TypeDirect peer
Description

Median Technologies provides AI-based imaging biomarkers and central imaging services for oncology clinical trials. Closely comparable to QMENTA's AI Imaging Biomarker catalog and Central Review offerings, particularly for oncology sponsors.

TypeDirect peer
Description

Calyx delivers clinical trial imaging management, central review, and regulatory submission support to pharma sponsors and CROs. Comparable to QMENTA's Trials and Central Review modules, and competes for the same enterprise imaging RFPs.

TypeBroad incumbent
Description

IQVIA is the largest global CRO with embedded clinical trial imaging capabilities and a broad services portfolio spanning RWD, EDC, and central labs. Comparable as a broad incumbent that competes for imaging budgets as part of larger outsourcing contracts rather than as a standalone platform.

TypeBroad incumbent
Description

Labcorp (formerly Covance) provides central lab and clinical trial services including imaging and biomarker workflows for global pharma. Comparable as a large incumbent offering imaging capabilities bundled within broader CRO and lab services.

TypeEmerging player
Description

Arterys offers a cloud-native AI medical imaging platform with FDA-cleared deep learning models across cardiac, lung, and liver workflows. Comparable as an emerging cloud AI imaging peer with overlapping regulatory-grade cloud positioning, though more focused on clinical care than clinical trials.

TypeEmerging player
Description

Aidoc provides AI-powered medical imaging analysis for clinical workflows in hospitals, with FDA-cleared algorithms for triage and detection. Comparable as an AI imaging peer with overlapping computer-vision capabilities, though primarily serving acute-care radiology rather than trial endpoints.

TypeEmerging player
Description

Viz.ai develops AI-driven imaging workflow and care coordination software, initially focused on stroke and expanding across other neuro and cardiovascular indications. Comparable as a regulated AI imaging company leveraging similar DICOM/NIfTI workflows and FDA-cleared models.

TypeEmerging player
Description

Subtle Medical provides AI-based image enhancement and acquisition acceleration for MRI and PET, used in both clinical and research settings. Comparable as an emerging AI imaging peer with overlapping neuro/cardiac use cases and FDA-cleared positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

QMENTA

Clinical Trial Medical Imaging Softwareqmenta.com

QMENTA is a Boston-based, FDA 510(k)-cleared cloud platform that provides AI-powered medical imaging analysis, automated quality control, and regulatory-grade data management for pharmaceutical sponsors, CROs, academic research institutions, and AI algorithm developers running clinical trials and neuroimaging research.

What QMENTA does

QMENTA (legal entity Mint Labs, Inc.) is a Boston-headquartered software company, founded in 2013, that operates a cloud-native AI imaging platform purpose-built for regulated clinical trials and neuroimaging research. The platform unifies imaging data ingestion (DICOM, NIfTI, BIDS formats), automated quality control, AI biomarker analysis, and regulatory-grade audit trails into a single governed data layer, with FDA 510(k) clearance and compliance with HIPAA, GDPR, and FDA Title 21 CFR Part 11. Core technical architecture is Docker-container-based and runs on hybrid cloud infrastructure (including Google Cloud Platform), exposing a Python SDK and Jupyter-compatible environment that enables third-party algorithm developers to package and distribute imaging AI tools via a revenue-sharing marketplace.

The company serves four primary customer segments: pharmaceutical sponsors and CROs running imaging endpoints in regulated trials (the primary segment), academic research institutions and imaging core labs, AI algorithm developers seeking a validated clinical deployment channel, and hospitals/healthcare providers. A secondary Legal vertical sells automated DTI quantification (Q-FiberMapper) to law firms and imaging centers on a pay-per-scan basis for TBI litigation. Revenue is generated through enterprise SaaS subscriptions (custom-priced, annual contracts for trials and core labs), usage-based analysis credits (freemium entry with 5 credits), SDK marketplace commissions, and tiered Neuro Data Services subscriptions (Tier 1-4 curated datasets). Named customers include Bayer, Amylyx, Cleveland Clinic, UCSF, NIH, Massachusetts General Hospital, and Alzamend Neuro, with the platform deployed across 250+ imaging sites and processing 16 million images covering 1.3 million subjects.

QMENTA goes to market through a hybrid motion combining direct enterprise field sales (targeting sponsors, CROs, and core labs) with product-led self-serve onboarding (free trial, 5 credits), event-driven demand generation at RSNA and CNS Summit, and developer relations via the SDK and GitHub community. Marketing channels emphasize thought leadership content, scientific case studies, and PR around regulatory milestones. Distribution covers North America (Boston HQ), Europe (Barcelona EU HQ), and an active expansion push into Asia-Pacific via a strategic advisor appointed in 2025. The company operates with 11-50 employees and has raised approximately $10M cumulatively across multiple small rounds since inception, with the most recent disclosed funding of $3.8M led by Flashpoint in July 2020.

QMENTA firmographics

Firmographics
Name
QMENTA
Legal name
Mint Labs, Inc.
Website
https://qmenta.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
QMENTA is a Boston-based, FDA 510(k)-cleared cloud platform that provides AI-powered medical imaging analysis, automated quality control, and regulatory-grade data management for pharmaceutical sponsors, CROs, academic research institutions, and AI algorithm developers running clinical trials and neuroimaging research.
Ownership category
akta.pro rank

QMENTA industry classification

Industry
Product category
Clinical Trial Medical Imaging Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • Medical imaging platform
  • Clinical trial imaging
  • Neuroimaging AI
  • Imaging biomarkers
  • Centralized image review

Where QMENTA is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

QMENTA business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. SaaS Platform Subscription: QMENTA operates as a cloud-based SaaS platform where customers pay subscription fees for access to the Imaging Hub, Central Review, and AI biomarker tools. Pricing is subscription-based, typically billed annually, with tiered plans based on usage volume, number of users, and analysis credits. Enterprise contracts cover sponsors, CROs, and core labs on a single platform.
  2. Usage-Based Analysis Credits: Customers receive or purchase analysis credits to run AI imaging biomarker tools and workflows on the platform. Each analysis consumes one credit regardless of workflow complexity. Free trial users receive 5 credits. Enterprise contracts define credit allocations and parallel analysis capacity.
  3. SDK / Tool Catalog Marketplace: Third-party developers integrate algorithms into QMENTA's tool catalog via the SDK under revenue-sharing agreements. QMENTA markets, distributes, and sells the tools, retaining a share of the revenue. This creates a marketplace commission stream.
  4. Neuro Data Services: Curated and annotated neurology imaging datasets sold in tiered levels (Tier 1–4), ranging from aggregated de-identified data to integrated multi-modal datasets with expert radiology assessments and genomic/Real World Data. Over 10 million neurology images have been exchanged or stored on the platform.
  5. Pay-per-Scan (Legal Product): The QMENTA Legal product (Q-FiberMapper for TBI litigation) operates on a pay-per-scan model with no commitment required, targeting law firms and imaging centers directly.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree Trial
SubscriptionAnnualSubscription Plans (Custom Enterprise)
Unit PricingPay-as-you-goLegal - Pay-per-Scan
SubscriptionMulti-year contractNeuro Data Services (Tiers 1–4)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

QMENTA product offering

Product offering

Core offering

QMENTA provides a cloud-native AI imaging platform for clinical trials and research that governs neuroimaging data from first scan through FDA submission. The platform combines an Imaging Hub (data ingestion, standardization, storage, AI biomarker analysis, and real-time quality control) with a Central Review capability for regulatory-grade endpoint review. QMENTA also operates an SDK-powered tool catalog marketplace for third-party AI algorithms and a curated Neuro Data Services offering across four data tiers.

Product overview

QMENTA is a cloud-native medical imaging platform for clinical trials and research, built as a unified platform-plus-modules architecture. The core QMENTA Platform provides the central infrastructure with the Imaging Hub as the primary interface, which encompasses the Imaging Management System, Smart Uploader, Imaging Cloud storage, and AI Imaging Biomarkers. The platform is offered in three product tiers: Trials (governed neuroimaging for regulated studies), Foundation (AI development and deployment), and Legal (TBI litigation). Key modules include the Central Review Platform for regulatory-grade imaging endpoint review and the SDK for custom algorithm integration. Neuro Data Services provides curated data across four tiers. The platform processes over 16 million images across 250+ sites with FDA 510(k) clearance and zero nonconformities in external pharma audits.

Differentiator

Problem solved

Functional benefit

Brands

  • Neuro Data Services: Curated real-world neurology imaging data services with tiered levels of augmented data for AI training, retrospective studies, and biomarker research.
  • Q-FiberMapper

Products and services

  • QMENTA Platform / Imaging Hub An all-in-one cloud-native imaging platform for clinical trials that provides governed neuroimaging data management, AI analysis, and regulatory-grade evidence production across disease areas, imaging modalities, and trial phases. Sold to pharmaceutical sponsors, CROs, core labs, academic centers, hospitals, and AI firms as the core enterprise offering.
  • Central Review Platform Regulatory-grade centralized image review system for imaging endpoints in long-duration oncology and CNS trials, providing longitudinal consistency monitoring, FDA Title 21 CFR Part 11-compliant electronic signatures, audit trails, and access controls. Sold to pharma sponsors, CROs, and core labs.
  • Neuro Data Services Curated real-world neurology imaging data service across four tiers: aggregated/tagged clinical data (Tier 1), disease-specific neuroimaging (Tier 2), expert radiology assessments (Tier 3), and integration with genomic/Real World Data (Tier 4). Sold to AI firms, pharma sponsors, and researchers.
  • QMENTA Software Development Kit (SDK) Python-based SDK and developer toolkit enabling algorithm developers to package, test, and distribute custom digital biomarker algorithms on the QMENTA platform via Docker containers, with monetization through a revenue-sharing tool catalog marketplace. Targeted at AI imaging biomarker developers.
  • Q-FiberMapper (Legal Product) Automated DTI quantification tool for TBI litigation that performs automated segmentation of 33 white matter fiber tracts. Sold on a pay-per-scan basis with no commitment required. Targeted at law firms and imaging centers handling TBI cases.

Quantifiable outcome

  • 81% cost reduction vs. on-premise imaging infrastructure ($600K vs. $3.2M) and $1.83M vs. cloud DIY for a 20-site clinical trial scenario
  • +6 more outcomes

Companies that use QMENTA

Customer profile

Named customers10 records

Segments5 records

Ideal customer profiles4 records

QMENTA technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability6 records

Feature8 records

QMENTA partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered key advisory, flagship, core, supporting and infrastructure.

  • Dr. Montserrat Barcelókey advisoryOthers · 11 March 2026Dr. Montserrat Barceló was appointed as strategic advisor to QMENTA to support global growth and enterprise expansion, with particular focus on Europe and Asia-Pacific markets. Barceló brings healthcare and clinical research leadership experience from TFS HealthScience, Veristat, and other organizations.
  • Alzamend NeuroflagshipStrategic or Co-development Partner · 3 June 2025Alzamend Neuro partnered with QMENTA to advance AI-powered imaging for its Phase II clinical trial of AL001 at Massachusetts General Hospital (MGH). QMENTA provides AI-powered imaging analysis for head-to-head studies comparing AL001 versus lithium carbonate products for lithium blood levels and neuroimaging endpoints.
  • EIT HealthcoreStrategic or Co-development PartnerQMENTA is partnered with EIT Health, a European initiative supported by the EU that fosters healthcare innovation. QMENTA's logo and partnership are displayed on its website, indicating collaborative alignment on healthcare innovation initiatives. EIT Health is listed as an official partner.
  • Curated Neurology Imaging Data PartnerssupportingOthersQMENTA's Neuro Data Services leverages a network of highly qualified partners to provide curated and annotated real-world neurology imaging and clinical data at four tiered levels. These partners provide data aggregation, disease-specific neuroimaging annotation, expert radiology assessments, and genomic/Real World Data integration.
  • Google Cloud PlatforminfrastructureTechnology or IntegrationQMENTA's privacy policy identifies Google Cloud Platform as a third-party data processor used both inside and outside the EEA. GCP provides cloud infrastructure and data storage services for the QMENTA platform.
  • HubSpotinfrastructureTechnology or IntegrationHubSpot is listed as a third-party data processor in QMENTA's privacy policy. Used for marketing automation, CRM, and website analytics. Data is processed both inside and outside the EEA.
  • AtlassianinfrastructureTechnology or IntegrationAtlassian is listed as a third-party data processor in QMENTA's privacy policy, used for internal collaboration and documentation management (e.g., Confluence, Jira).

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

QMENTA competitors and assessment

Company assessment

Direct peers

  • Clario: Clario is a clinical trial imaging and endpoint services company offering central reading, image management, and AI-enabled analytics for pharma and CROs. Directly comparable to QMENTA's Trials and Central Review products for the same sponsor and CRO buyer set.
  • Medidata (Dassault Systèmes): Medidata's Rave Imaging provides central imaging management, reviewer workflows, and AI biomarker integration within a leading EDC platform. Highly comparable to QMENTA's governed imaging data layer for regulated trials, with a much larger installed base in pharma R&D.
  • Median Technologies: Median Technologies provides AI-based imaging biomarkers and central imaging services for oncology clinical trials. Closely comparable to QMENTA's AI Imaging Biomarker catalog and Central Review offerings, particularly for oncology sponsors.
  • Calyx (formerly ERT): Calyx delivers clinical trial imaging management, central review, and regulatory submission support to pharma sponsors and CROs. Comparable to QMENTA's Trials and Central Review modules, and competes for the same enterprise imaging RFPs.

Broad incumbents

  • IQVIA: IQVIA is the largest global CRO with embedded clinical trial imaging capabilities and a broad services portfolio spanning RWD, EDC, and central labs. Comparable as a broad incumbent that competes for imaging budgets as part of larger outsourcing contracts rather than as a standalone platform.
  • Labcorp Drug Development: Labcorp (formerly Covance) provides central lab and clinical trial services including imaging and biomarker workflows for global pharma. Comparable as a large incumbent offering imaging capabilities bundled within broader CRO and lab services.

Emerging players

  • Arterys: Arterys offers a cloud-native AI medical imaging platform with FDA-cleared deep learning models across cardiac, lung, and liver workflows. Comparable as an emerging cloud AI imaging peer with overlapping regulatory-grade cloud positioning, though more focused on clinical care than clinical trials.
  • Aidoc: Aidoc provides AI-powered medical imaging analysis for clinical workflows in hospitals, with FDA-cleared algorithms for triage and detection. Comparable as an AI imaging peer with overlapping computer-vision capabilities, though primarily serving acute-care radiology rather than trial endpoints.
  • Viz.ai: Viz.ai develops AI-driven imaging workflow and care coordination software, initially focused on stroke and expanding across other neuro and cardiovascular indications. Comparable as a regulated AI imaging company leveraging similar DICOM/NIfTI workflows and FDA-cleared models.
  • Subtle Medical: Subtle Medical provides AI-based image enhancement and acquisition acceleration for MRI and PET, used in both clinical and research settings. Comparable as an emerging AI imaging peer with overlapping neuro/cardiac use cases and FDA-cleared positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

QMENTA social profiles

Digital presence

QMENTA compliance and trust

Trust signal

Compliance4 records

QMENTA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

QMENTA leadership team

Management profile

Number of profiles

Profiles10 records

QMENTA funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

QMENTA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QMENTA

What does QMENTA do?

QMENTA provides a cloud-native AI imaging platform for clinical trials and research that governs neuroimaging data from first scan through FDA submission. The platform combines an Imaging Hub (data ingestion, standardization, storage, AI biomarker analysis, and real-time quality control) with a Central Review capability for regulatory-grade endpoint review. QMENTA also operates an SDK-powered tool catalog marketplace for third-party AI algorithms and a curated Neuro Data Services offering across four data tiers.

Is QMENTA a public or private company?

QMENTA is a private company. It is classified as venture growth investor backed and is currently operating.

When was QMENTA founded?

QMENTA was founded in 2013. It employs 11 to 50 people.

Where is QMENTA based?

QMENTA is headquartered in Boston, United States, in the North America region.

How does QMENTA make money?

Five revenue lines are on record. SaaS Platform Subscription is the primary driver. The others are usage-Based Analysis Credits, SDK / Tool Catalog Marketplace, neuro Data Services and pay-per-Scan (Legal Product).

Who are QMENTA's main competitors?

Direct peers on record are Clario, Medidata (Dassault Systèmes), Median Technologies and Calyx (formerly ERT). Broad incumbents are IQVIA and Labcorp Drug Development. Emerging players are Arterys, Aidoc, Viz.ai and Subtle Medical.

Does QMENTA have an API?

Yes. The QMENTA API is a limited, revocable, non-exclusive, non-transferable, non-sublicenseable license that allows subscribers to access the API to manage their data. The SDK enables developers to connect the QMENTA Platform with third-party software for fetching input data, starting binaries/scripts, and uploading result files. The SDK uses Docker containers running on QMENTA's hybrid cloud infrastructure, enabling custom tool integration and analysis workflows. Python is the primary language for SDK development. Developer documentation is at docs.qmenta.com/sdk.

What industry is QMENTA in?

QMENTA's product category is Clinical Trial Medical Imaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 54151 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireQMENTA Launches Central Review in line with FDA Real-Time Clinical Trials Requirements for ImagingQMENTA announced Central Review, an end-to-end platform for imaging central review in clinical trials, covering site upload, blinded multi-reader assessment, adjudication, QA, and locked database export. The system is 21 CFR Part 11-compliant and links all prior scans for each subject, with a two-month trial and a June 25 webinar.EIN PresswireQMENTA Appoints Dr. Montserrat Barceló as Strategic Advisor to Support Global Growth and Enterprise ExpansionQMENTA, a Barcelona-based neuroimaging AI company, appointed Dr. Montserrat Barceló as strategic advisor to support global growth and enterprise expansion. Dr. Barceló brings over three decades of CRO leadership experience, including serving as Global COO at TFS HealthScience managing 200+ customers and 750+ professionals across 25 locations worldwide. In this advisory role, she will work with QMENTA's leadership team on growth strategy, enterprise positioning, and international expansion with a focus on European and Asia-Pacific markets.DoitCloud Consulting: Types of Services and BenefitsThe article outlines the essential role of cloud consulting in managing complex multicloud environments, highlighting services such as strategy planning, migration, optimization, and security. It specifically promotes DoiT's integrated platform and advisory services for cost reduction and operational efficiency. The text references case studies from clients QMENTA, Bdeo, and Launchmetrics to demonstrate tangible benefits like significant cloud spend savings.openPR.comGlobal Neuroimaging Software Market Size, Share and Forecast By Key Players-IXICO,QMENTA,Cortechs.ai,Quantib,BrainomixThe global neuroimaging software market is projected to grow from $9.62 billion in 2024 to $20.02 billion by 2031, a CAGR of 12.99%. Growth is driven by demand for brain imaging in diagnostics and research, with Asia-Pacific expected to be the fastest-growing region.NewswireQenta, Inc. unveils first comprehensive financial services and technology platforms for emerging marketsQenta unveiled an integrated suite of financial services for emerging markets, including tokenization, payments, and risk management. The company targets an addressable market over $500 billion, with emerging markets expected to be a majority revenue contributor by 2026. Qenta conducts over 1.4 million transactions monthly with 5,000 active customers.QMENTACloud AI Medical Imaging Expert QMENTA, Inc. Announces FDA 510(k) Clearance of Platform at RSNA 2021QMENTA announced FDA 510(k) clearance for its QMENTA Platform for Care, enabling physicians to manage imaging data and use AI tools. The clearance, K202718, covers over 50 AI algorithms for neurology analysis. The company will be at booth 6633 at RSNA 2021.Martinos CenterMartinos Center Joins QMENTA, University of Rochester in Announcing the Results of the ‘IronTract Challenge’The Martinos Center, University of Rochester, and QMENTA concluded the IronTract Challenge, which evaluated diffusion MRI tractography algorithms against histological ground truth. Prizes were awarded to G. Girard, B. Aydogan, and M. Mancini for high algorithmic accuracy. A webinar is planned in early 2021 to celebrate winners and discuss collaboration.QMENTAResults of the Final PhaseThe Martinos Center, University of Rochester, and QMENTA announced the IronTract Challenge results, where global researchers competed to improve Diffusion MRI tractography accuracy. G. Girard won first prize, with B. Aydogan and M. Mancini taking second and third. QMENTA will host a webinar in early 2021 to celebrate and share insights.QMENTAQMENTA’s AI Platform Selected for the CAVS-MS Multiple Sclerosis Biomarker Study Funded By the National Institute of HealthQMENTA's AI platform was selected for Phase II of the NIH-funded CAVS-MS study, which tests the central vein sign as a biomarker for multiple sclerosis. The platform will coordinate data from 400 individuals across study sites, aiming to reduce inaccurate diagnoses. The company's CEO said the work aims to simplify data analysis and free researchers for discovery.QMENTAQMENTA Launches Medical Imaging AI Initiative In COVID-19 BattleQMENTA launched #ConquerCovid, a collaborative initiative to centralize and analyze COVID-19 medical imaging data. The company will donate its AI-powered cloud platform for researchers to develop AI tools that detect and track the virus. The initiative follows a partnership with MSDA and MSIF to study COVID-19 effects on multiple sclerosis patients.